Research Paper Volume 4, Issue 10 pp 715—722
New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis
Figure 3. Rapatar delays development of lymphomas in p53−/− mice. (A) Representative initial lymphoma developed in control mouse at the age of 101 days. (B) Similar appearance of lymphoma in Rapatar-treated mouse at 281 days of age. Both A and B show monotonous infiltrate of medium-sized neoplastic cells with round nuclei, fine chromatin, indistinct nucleoli, and numerous mitotic figures and apoptotic cells. (C) Advanced lymphoma in 134-day old control mouse with metastases in liver (D) and lung (E). (D) Metastasis in liver showing the extensive spread of neoplastic cells effaces the normal structure and only minimal remnants of hepatocytes (marked by arrows). (E) Metastasis in the lung showing neoplastic infiltrates in perivascular area and in the alveolar walls (arrows) (F) Advanced lymphoma with pathological changes similar to shown in C in the thymus of 241day-old Rapatar-treated animal with metastasis in liver (G) and lung (H). (G) Metastasis in liver showing neoplastic infiltrates in portal tract (yellow arrow) and sinusoids (white arrow). (H) Metastasis in the lung showing perivascular neoplastic infiltrate (arrow).